Clinical trials: Superficial Vein Thrombosis
Superficial Vein Thrombosis
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus fondaparinux in the treatment of superficial vein thrombosis (SVT).
- Trial name
- NCT01499953
- Testing
- Rivaroxaban, Fondaparinux
- Where
- 23 sites in Germany
- Volunteers
- 472 people
- Sponsor
- GWT-TUD GmbH
Thrombosis, Venous
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of acute (recent) superficial thrombophlebitis.
- Trial name
- NCT00443053
- Where
- 227 sites in Bulgaria, Czechia and 15 more
- Volunteers
- 3,002 people
- Sponsor
- GlaxoSmithKline
Thromboembolic Complications
Thrombelastography Based Dosing of Enoxaparin
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs.
- Trial name
- NCT00990236
- Testing
- Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Oregon Health and Science University
Catheter Infection, Catheter Thrombosis
Midlines and Thrombophlebitis
Peripherally inserted central catheters (PICCs) are central catheters that are placed via peripheral vein under ultrasound guidance and may be used for patients with difficult venous access for long-term central or peripheral…
- Conditions
- Catheter Infection, Catheter Thrombosis, Catheter Complications
- Trial name
- NCT03725293
- Testing
- Angiodynamics BioFlo Midline Catheter, Teleflex Arrowg+ard Blue Advanced Midline Catheter
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- Corewell Health East